Predicting Individual Survival After Hepatectomy for Hepatocellular Carcinoma: a Novel Nomogram from the “HCC East & West Study Group”

Journal of Gastrointestinal Surgery

Volumn 20, Issue 6, 2016, Pages 1154-1162

  Torzilli, Guido ^a   Donadon, Matteo ^a   Belghiti, Jacques ^b   Kokudo, Norihiro ^c   Takayama, Tadatoshi ^d   Ferrero, Alessandro ^e   Nuzzo, Gennaro ^f   Vauthey, Jean Nicolas ^g   Choti, Michael A ^h   De Santibanes, Eduardo ⁱ   Makuuchi, Masatoshi ^j  

^a HUMANITAS UNIVERSITY   (Italy)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITY OF TOKYO   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e MAURIZIANO HOSPITAL   (Italy)

^f UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^j JAPANESE RED CROSS MEDICAL CENTER   (Japan)

more..

Author keywords

Hepatectomy; Hepatocellular carcinoma; Nomogram; Survival

Indexed keywords

BILIRUBIN;

ADOLESCENT; ADULT; AGED; BLOOD; BLOOD VESSEL; CHILD; CLINICAL TRIAL; COMPLICATION; DISEASE FREE SURVIVAL; ESOPHAGUS VARICES; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; NOMOGRAM; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR INVASION; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; BLOOD VESSELS; CARCINOMA, HEPATOCELLULAR; CHILD; DISEASE-FREE SURVIVAL; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEPATECTOMY; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NOMOGRAMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN; YOUNG ADULT;

EID: 84961848402     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-016-3132-0     Document Type: Article

References (32)

1. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009;44(S19):96–101.
2. Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15(S4):5–13.
3. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35–43.
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693–699.
5. Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013;257:929–37.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
7. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430.
8. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–338.
9. Terminology Committee of the IHPBA (authors). Terminology of liver anatomy and resections. HPB Surg 200;2:333–339.
10. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.
11. Groenwold RH, Hak E, Hoes AW. Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies. J Clin Epidemiol 2009;62:22–28.
12. Harrell Jr. FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–387.
13. Bruix J, Fuster J. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group. Ann Surg 2015;262:e30.
14. Mazzaferro V, Roayaie S, Poon R, et al. Dissecting EASL/AASLD recommendations with a more careful knife: a comment on “surgical misinterpretation” of the BCLC staging system. Ann Surg 2015;262:e17-18.
15. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018–22.
16. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62–67.
17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
18. Torzilli G, Belghiti J, Kokudo N, et al. Reply to the Letter to the Editor titled “Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on ‘Surgical Misinterpretation’ of the BCLC Staging System”: Real Misinterpretation or Lack of Clarity within the BCLC? Ann Surg 2015;262:e18-19.
19. Torzilli G, Belghiti J, Kokudo N, et al. Reply to the letter to the editor entitled “A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group”: when the study setting “ignores” the patients. Ann Surg 2015;262:e30-31.
20. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005; 03:402–408.
21. Sternberg CN. Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol 2006;24:3819–3820.
22. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437–2444.
23. Cho CS, Gonen M, Shia J, et al. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg 2008;206:281–291.
24. Shim JH, Jun MJ, Han S, et al. Prognostic Nomograms for Prediction of Recurrence and Survival After Curative Liver Resection for Hepatocellular Carcinoma. Ann Surg 2014;261:939–946.
25. Edge SB (2009) AJCC Cancer Staging Manual (ed 7) Springer-Verlag, New York.
26. Liver Cancer Study Group of Japan, Okamoto E (1997) Classification of Primary Liver Cancer.
27. Capussotti L, Ferrero A, Vigano L, et al. Portal hypertension: contraindication to liver surgery? World J Surg 2006;30:992–999.
28. Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009; 250:922–928.
29. Torzilli G, Donadon M, Marconi M, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg 2008;143:1082–1090.
30. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995–2004.
31. Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2014;20:3112–3124.
32. Zender L, Villanueva A, Tovar V, et al. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921–929.